Loho Imelda Maria, Siregar Lianda, Waspodo Agus Sudiro, Hasan Irsan
Gastroenterology and Hepatology Department, Dharmais National Cancer Center Hospital, Jakarta, Indonesia.
Acta Med Indones. 2018 Oct;50(4):353-360.
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death worldwide. This is due to the heterogeneity of the tumor biology and lack of curative treatment options. The most significant prognostic factor is detection at early stage and thus, surveillance strategies are of high importance. High-risk patients should undergo ultrasound and tumor marker tests at six-month interval in order to detect HCC at the earlier stage. However, in real-life practice, ultrasound has several limitations and the adherence to HCC surveillance is suboptimal due to various provider, patient, and health-care system factors. In this paper, we will address current methods of HCC surveillance and obstacles found in real-life practice.
肝细胞癌（HCC）是全球癌症相关死亡的第二大常见原因。这是由于肿瘤生物学的异质性以及缺乏治愈性治疗方案。最重要的预后因素是早期检测，因此，监测策略至关重要。高危患者应每六个月进行一次超声和肿瘤标志物检测，以便在早期发现HCC。然而，在实际临床实践中，超声存在若干局限性，并且由于各种医疗服务提供者、患者和医疗保健系统因素，对HCC监测的依从性并不理想。在本文中，我们将探讨目前HCC监测的方法以及在实际临床实践中发现的障碍。
